Brilinta Archives -

AstraZeneca has lifted the veil on the large-scale THALES trial of its antiplatelet drug Brilinta in stroke, the

Chasing Brilinta payoff, AZ details THALES data in ischemic stroke

https://pharmaphorum.com/news/chasing-brilinta-payoff-az-details-thales-data-in-ischemic-stroke/

The FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce

FDA grants fast review of AZ’s Brilinta to prevent recurring strokes

https://pharmaphorum.com/news/az-grants-fast-review-of-astrazenecas-cardiovascular-diseases-drug-brilinta/

AstraZeneca’s anti-platelet drug Brilinta has been cleared in the US for a major new indication, preventing a first

AZ claims FDA okay for Brilinta in coronary artery disease patients

https://pharmaphorum.com/news/az-claims-fda-okay-for-brilinta-in-coronary-artery-disease-patients/

A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients.

New heart attack data boost AZ’s Brilinta

https://pharmaphorum.com/news/new-heart-attack-data-boost-azs-brilinta/

Brilinta will not hit $3.5bn sales target, company admits.

AZ feels pain after heart drug fails again

https://pharmaphorum.com/news/az-feels-pain-heart-drug-fails/

Recommendation will add to growth trajectory

Brilique boosted by NICE’s long-term prevention recommendation

https://pharmaphorum.com/news/brilique-boosted-nices-long-term-prevention-recommendation/

Brilinta